Last reviewed 2026-04-23 · How we verify

NAFT-500

NAFT-500 is a naftifine derivative designed to modulate skin barrier function and reduce inflammation in dermatological conditions.

NAFT-500 is a naftifine derivative designed to modulate skin barrier function and reduce inflammation in dermatological conditions. Used for Fungal skin infection (specific indication under phase 3 evaluation).

At a glance

Mechanism of action

Naftifine is a benzylamine antifungal agent that inhibits fungal sterol synthesis; NAFT-500 appears to be a formulation or derivative variant being developed for topical dermatological use. The phase 3 development suggests evaluation in a specific skin condition, likely fungal infection or inflammatory dermatosis where naftifine's antifungal and anti-inflammatory properties are therapeutically relevant.

Approved indications

• Fungal skin infection (specific indication under phase 3 evaluation)

Common side effects

• Local skin irritation
• Erythema
• Pruritus

Key clinical trials

• Pharmacokinetic Study of Pediatric Subjects With Tinea Cruris and Tinea Pedis (PHASE4)
• Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Pedis (PHASE3)
• Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Cruris (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• NAFT-500 CI brief — competitive landscape report
• NAFT-500 updates RSS · CI watch RSS
• Merz North America, Inc. portfolio CI